Gastroenterology
Volume 123, Issue 4 , Pages 1129-1134 , October 2002

Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs

Received 14 March 2002 ,Accepted 20 June 2002.

References 

  1. Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Arndorfer RC, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest. 1980;65:256–267
  2. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995;109:601–610
  3. Lehmann A, Antonsson M, Bremner-Danielsen M, Flärdh M, Hansson-Brändén L, Kärrberg L. Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology. 1999;117:1147–1154
  4. Blackshaw LA, Staunton E, Lehmann A, Dent J. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol. 1999;277:G867–G874
  5. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in normal subjects. Gastroenterology. 2000;118:7–13
  6. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002;50:19–24
  7. Partosoedarso ER, Young RL, Blackshaw LA. GABA(B) receptors on vagal afferent pathways: peripheral and central inhibition. Am J Physiol. 2001;280:G658–G668
  8. Bowery NG, Enna SJ. γ-Aminobutyric acidB receptors: first of the functional metabotropic heterodimers. J Pharmacol Exp Ther. 2000;292:2–7
  9. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74:129–180
  10. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404:84–87
  11. Simoneau II , Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, et al. The cannabinoid agonist WIN55,212-2 suppresses opiod-induced emesis in ferrets. Anesthesiology. 2001;94:882–887
  12. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001;121:767–774
  13. Darmani NA. The cannabinoid CB1 receptor antagonist SR141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001;430:49–58
  14. Hornby P. Central neurocircuitry associated with emesis. Am J Med. 2001;111:106S–112S
  15. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem. 1999;6:635–664
  16. Diana MA, Levenes C, Mackie K, Marty A. Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci. 2002;22:200–208
  17. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410:588–592
  18. Smid SD, Young RL, Cooper NJ, Blackshaw LA. GABABR expressed on vagal afferent neurones inhibits gastric mechanosensitivity in ferret proximal stomach. Am J Physiol. 2001;281:G1494–G1501
  19. Stakeberg J, Lehmann A. Influence of different intragastric stimuli on triggering of transient lower oesophageal sphincter relaxation in the dog. Neurogastroenterol Motil. 1999;11:125–132
  20. Lehmann A, Brändén L. Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog. Eur J Pharmacol. 2001;431:253–258
  21. Cox MR, Martin CJ, Dent J, Westmore M. Effect of general anaesthesia on transient lower oesophageal sphincter relaxations in the dog. Aust N Z J Surg. 1988;58:825–830
  22. Pertwee RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci. 1999;65:597–605
  23. Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology. 1995;109:1547–1554
  24. Boulant J, Fioramonti J, Dapoigny M, Bommelaer G, Bueno L. Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxations to gastric distention in dogs. Gastroenterology. 1994;107:1059–1066
  25. Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology. 1997;113:409–414
  26. Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther. 1998;12:761–766
  27. Finizia C, Lundell L, Cange L, Ruth M. The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2002;14:9–14
  28. Lidums I, Hebbard GS, Holloway RH. Effect of atropine on proximal gastric motor and sensory function in normal subjects. Gut. 2000;47:30–36
  29. Izzo AA, Mascolo N, Tonini M, Capasso F. Modulation of peristalsis by cannabinoid CB1 ligands in the isolated guinea-pig ileum. Br J Pharmacol. 2000;129:984–990
  30. Coutts AA, Brewster N, Ingram T, Razdan RK, Pertwee RG. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br J Pharmacol. 2000;129:645–652
  31. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol. 1995;73:907–910
  32. Himmi T, Perrin J, El Ouazzani T, Orsini J-C. Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol. 1998;359:49–54
  33. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice ASC, Elphick MR. Cannabinonid CB1 receptor expression in rat spinal cord. Mol Cell Neurosci. 2000;15:510–521

☆ Address requests for reprints to: Anders Lehmann, Ph.D., Gastrointestinal Biology, Integrative Pharmacology, AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden. e-mail Anders.Lehmann@astrazeneca.com; fax: (46) 31 776 3747.

☆☆ Supported by AstraZeneca R&D Mölndal.

PII: S0016-5085(02)00218-4

doi: 10.1053/gast.2002.36025

Gastroenterology
Volume 123, Issue 4 , Pages 1129-1134 , October 2002

Article Tools

* Image Usage & Resolution